Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 34

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
   (79,000)Provision for expected credit losses   -   (2,374)  -   (2,374)OPERATING EXPENSES  (290,544)  (1,452,543)  (386,598)  (2,129,685)                 LOSS FROM OPERATIONS  (267,327)  (683,697)  (386,598)  (1,337,622)                 FINANCE COSTS  (3,764)  (2,415)  (14)  (6,193)                 LOSS BEFORE TAX  (271,091)  (686,112)  (386,612)  (1,343,815)                 Tax expense  -   (1,555)  -   (1,555)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(271,091) $(687,667) $(386,612) $(1,345,370)

 26Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Three months for period ended September 30, 2025              REVENUE $4,768  $2,539,055  $-  $2,543,823                  COST OF REVENUE  (864)  (2,165,274)  -   (2,166,138)                 GROSS PROFIT  3,904   373,781   -   377,685                  OTHER INCOME                Dividend income   -   4,192   -   4,192 Interest income  18,552   2,226   -   20,778 Gain on disposal of investments in equity securities  -   42